Korean J Psychopharmacol.
2008 May;19(3):147-155.
Efficacy and Safety of Aripiprazole during Acute Treatment Phase in Patients with Schizophrenia, Schizophreniform Disorder and Schizoaffective Disorder: An 8-Week, Prospective, Open-Label Study
- Affiliations
-
- 1Department of Psychiatry, Seoul National University College of Medicine, Seoul, Korea. kwonjs@plaza.snu.ac.kr
- 2Department of Psychiatry, Hallym University College of Medicine, Chuncheon Sacred Heart Hospital, Chuncheon, Korea.
- 3Department of Psychiatry, Ansan Hospital, Korea University College of Medicine, Ansan, Korea.
- 4Department of Neuropsychiatry, Maryknoll General Hospital, Busan, Korea.
- 5Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, Korea.
- 6Department of Psychiatry, Yong-In Mental Hospital, Yongin, Korea.
- 7Department of Psychiatry, Naju National Hospital, Naju, Korea.
- 8Paik Institute for Clinical Research, Inje University, Busan, Korea.
- 9Department of Psychiatry, Hallym University College of Medicine, Anyang, Korea.
- 10Department of Psychiatry, Chonbuk National University College of Medicine, Jeonju, Korea.
- 11Department of Psychiatry, Chonnam National University Medical School, Gwangju, Korea.
Abstract
OBJECTIVE
The purpose of the present study was to investigate the efficacy, safety, and tolerability of aripiprazole in patients with schizophrenia, schizophreniform disorder, and schizoaffective disorder during acute treatment phase.
METHODS
Prospective, multicenter, single group, and 8-week study was conducted in patients with schizophrenia, schizophreniform disorder, and schizoaffective disorder. A total of 300 patients were enrolled in the present study. The primary efficacy measure was the Positive and Negative Syndrome Scale (PANSS) total score, and secondary efficacy measures were the PANSS positive and negative subscales scores, and Clinical Global Impression-Severity of Illness (CGI-S) score. Treatment-emergent adverse events, extrapyramidal symptoms (EPS), weight, vital signs, and laboratory tests were assessed as measures of tolerability and safety.
RESULTS
Significant improvements in all efficacy measures were achieved by aripiprazole as early as 1-week and sustained through 8-week period. First-episode patients showed greater improvements in PANSS total, positive subscale score, and CGI-S score, compared with recurrent patients. Slightly increased akathisia (+0.32 from baseline score of Barnes Akathisia Rating Scale, p=0.033) and weight gain (1.15+/-3.44 kg, p<0.001) were observed by aripiprazole during 8-week acute treatment phase.
CONCLUSION
The present study demonstrated that aripiprazole was effective in acute treatment of positive and negative symptoms of schizophrenia, schizophreniform disorder, and schizoaffective disorder. In general, aripiprazole showed favorable safety and tolerability profiles, although clinicians needed to pay attention to the possibility of akathisia and weight gain by aripiprazole in first-episode patients during acute treatment phase.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Efficacy and Safety of Long-term Aripiprazole Therapy in Patients with Schizophrenia, Schizophreniform Disorder, and Schizoaffective Disorder: A 52-week, Prospective, Open-label Study
- Schizoaffective Disorder
- Effects of Psychoeducation Program on Insight and Treatment Attitudes in Patients with Schizophrenia, Schizophreniform Disorder, and Schizoaffective Disorder
- Effect of Long-Term Aripiprazole Therapy on Social Functioning in Korean Patients with Schizophrenia: A 52-Week, Prospective, Open-Label Study
- Eight-Week Prospective Open-Label Trial of the Treatment Efficacy of Aripiprazole in Children with Tourette Syndrome
